Viking Therapeutics Initiates Clinical Trial For VK5211 - Quick Facts

(RTTNews) - Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company focused on the development of therapies for metabolic and endocrine disorders, announced that the company has initiated the clinical development program for VK5211, its lead program for muscle and bone disorders. Investigators have dosed the first subjects in the initial portion of the VK5211 clinical program.

VK5211 is an orally available, non-steroidal selective androgen receptor modulator being developed for the treatment of patients recovering from non-elective hip fracture surgery.

The VK5211 clinical program will be followed by a randomized, double-blind, parallel group, placebo-controlled Phase 2 study to evaluate the efficacy, safety and tolerability of VK5211 in patients recovering from hip fracture surgery. Viking anticipates that the first patient in the efficacy study will be dosed in the fourth quarter of 2015.